Janus Henderson Group PLC Increases Holdings in Guardant Health, Inc. (NASDAQ:GH)

Janus Henderson Group PLC lifted its position in Guardant Health, Inc. (NASDAQ:GH) by 16.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,578 shares of the company’s stock after buying an additional 8,432 shares during the period. Janus Henderson Group PLC’s holdings in Guardant Health were worth $1,390,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. JNBA Financial Advisors bought a new position in Guardant Health in the third quarter worth approximately $26,000. Ashton Thomas Securities LLC bought a new position in Guardant Health in the 3rd quarter worth $34,000. Quarry LP purchased a new position in Guardant Health during the second quarter valued at $44,000. Canton Hathaway LLC bought a new stake in Guardant Health during the second quarter valued at about $59,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Guardant Health in the second quarter worth about $71,000. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Sanford C. Bernstein dropped their target price on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. The Goldman Sachs Group raised their price target on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, November 7th. UBS Group boosted their price objective on Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, August 21st. Finally, Leerink Partners cut their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Fifteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $40.60.

Insider Buying and Selling at Guardant Health

In related news, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the transaction, the director now directly owns 7,648 shares in the company, valued at approximately $228,675.20. This represents a 27.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Guardant Health Trading Down 0.5 %

GH stock opened at $34.76 on Friday. The firm has a fifty day moving average price of $27.92 and a 200 day moving average price of $28.13. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $38.53. The firm has a market cap of $4.29 billion, a PE ratio of -8.20 and a beta of 1.26. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. During the same quarter last year, the firm earned ($0.73) earnings per share. The business’s quarterly revenue was up 33.9% on a year-over-year basis. Sell-side analysts anticipate that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.